Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Phase 4

Completed

Conditions: Meningococcal Disease

Interventions: Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine

Registration Number: NCT01823536

Lead Sponsor: Novartis Vaccines

Brief Summary: In this extension study, V59P20E1, the sponsor was planning to assess 5-year antibody persistence in subjects who received one or two doses of MenACWY conjugate vaccine at 2 to 10 years of age, and to evaluate response to a booster dose administered 5 years after primary vaccination in the parent study V59P20 (NCT00616421).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 465

Inclusion Criteria

In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.

Subject has (a) parent(s) or legal guardian(s) who has/have given written consent after the nature of the study has been explained according to local regulatory requirements.
If the subject is of an age where, according to local regulations, informed assent is required, that subject has provided assent to participate in the study.
Subject is in good health as determined by the outcome of medical history, physical examination, and clinical judgment of the investigator.
A negative urine pregnancy test is required before female subjects of childbearing potential will be enrolled. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.
For subjects who participated in study V59P20 (Groups MenACWYCRM_ 2 (≥7-≤10 Years), MenACWYCRM_1 (≥7-≤10 Years) and MenACWYCRM_ 1 (≥11-≤15 Years) only):
- subject who enrolled in Groups MenACWYCRM_2 (≥7-≤10 Years), MenACWYCRM_1 (≥7-≤10 Years) and MenACWYCRM_1 (≥11-≤15 Years) of study V59P20, has completed this study and included in per protocol immunogenicity analysis;
- the date of first vaccination in study V59P20 occurred 54 to 66 months prior to the collection of the blood sample at Visit 1.
For vaccine-naive subjects (Groups Vaccine Naive(≥7-≤10Years) and Vaccine Naive (≥11-≤15 Years) only):
- Individual is a male or female 7 to 10 years of age (group Vaccine Naive(≥7-≤10Years)) or 11 to 15 years of age (Group Vaccine Naive (≥11-≤15 Years)).

Exclusion Criteria

In order to participate in this study, all subjects must meet NONE of the exclusion criteria described.

If the subject is female of childbearing potential, sexually active, and has not used any of the acceptable contraceptive methods for at least 2 months prior to study entry and for the duration of the trial.
Subject is a pregnant or breast-feeding female.
Subjects' parents or legal guardians or subjects who are not able to comprehend and to follow all required study procedures for the whole period of the study.
History of documented or suspected invasive meningococcal disease.
Previous household contact with and/or intimate exposure to an individual with laboratory proven N. meningitidis infection within 60 days prior to enrollment and for the duration of the study.
Have received any other meningococcal vaccine since participation in V59P20 or, if vaccine-naive subjects, have not received any meningococcal vaccine since birth.
Suspected or known hypersensitivity reaction after a previous dose of Menveo, any component of this vaccine, including any other CRM197 and diphtheria toxoid.
Any contraindication or precaution against vaccination with Novartis Menveo™ vaccine as highlighted in the package insert.
Serious, chronic, or acute illnesses or diseases (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system).
Any confirmed or suspected condition with impaired/altered function of immune system (immunodeficient or autoimmune conditions).
Administration of any cancer chemotherapy, immune-modified or immunosuppressive agents or systemic corticosteroids for at least seven days at any dose in the past 12 weeks or planned use throughout the study period (nasal or inhaled steroids are permitted, as are steroids applied to the skin).
Administration of blood, blood products and/or plasma derivatives or any immunoglobulin preparation in the past 12 weeks or planned use throughout the study period.
Administration of any vaccine within 28 days prior to the study enrollment or planned administration during the study period.
Subjects participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the study period.
Subjects who have experienced a significant acute infection requiring systemic antibiotic treatment within the 5 days prior to enrolment or have experienced a body temperature ≥38°C (≥100.4°F) within the 3 days before the intended study vaccination.
Any condition which, in the opinion of the investigator, would pose a health risk to the participant.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MenACWY-CRM (≥7-≤10 years of age)	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
Vaccine naive (≥11-≤15 years of age)	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
MenACWY-CRM_1 (≥7-≤10 years of age)	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
Vaccine naive (≥7-≤10 years of age)	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
MenACWY-CRM_1 (≥11-≤15 years of age)	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.

Primary Outcome Measures

Name	Time	Method
Percentages of Subjects With Persisting hSBA Titers ≥1:8 Against Neisseria Meningitidis (N. Meningitidis) Serogroups A, C, W and Y, Five Years After Having Received One or Two Doses of MenACWY-CRM Vaccine	5 years post-vaccination	The percentages of subjects with persisting serum bactericidal antibody ≥1: 8, against N.meningitidis serogroups A, C, W and Y, after having received one or two doses of MenACWY-CRM vaccine, five years earlier in the parent study, are reported. The serum bactericidal antibodies directed against N.meningitidis serogroups, are measured by human complement Serum Bactericidal Assay (hSBA).

Secondary Outcome Measures

Name	Time	Method
Persisting Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W and Y in Subjects, Five Years After Having Received One or Two Doses of MenACWY-CRM Vaccine.	5 years post-vaccination	The persistence of geometric mean titers (GMTs) against N.meningitidis serogroups A, C, W and Y in subjects who had received one or two doses of MenACWY-CRM vaccine, five years earlier in the parent study, are reported.
Percentages of Subjects With Persisting hSBA Titers ≥1:8 Against N.Meningitidis Serogroups A, C, W and Y as Compared to Age Matched Vaccine-naive Subjects	5 years post-vaccination; baseline for naive	The percentages of subjects with persisting serum bactericidal antibody ≥1: 8, against N.meningitidis serogroups A, C, W and Y, after having received one or two doses of MenACWY-CRM vaccine five years earlier in the parent study, are compared with the hSBA response in age matched vaccine-naive subjects.
Percentages of Subjects With hSBA Titers ≥1:8 Against N.Meningitidis Serogroups A, C, W and Y, After Receiving One Injection of MenACWY-CRM Vaccine in the Present Study.	Day 28 post-vaccination	The antibody response against N.meningitidis serogroups A, C, W and Y, at one month after one injection of Men ACWY-CRM vaccine was administered in the present study to subjects who had received either one or two doses of MenACWY-CRM vaccine 5 years earlier and to age matched naive subjects, is evaluated in terms of the percentages of subjects with hSBA titers ≥1:8.
Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W and Y, After Receiving One Injection of MenACWY-CRM Vaccine in the Present Study.	Day 28 post-vaccination	The antibody response against N.meningitidis serogroups A, C, W and Y, at one month after one injection of Men ACWY-CRM vaccine was administered in the present study to subjects who had received either one or two doses of MenACWY-CRM vaccine 5 years earlier and to age matched naive subjects, is evaluated in terms of GMTs.
Number of Subjects Reporting Solicited Adverse Events, After Receiving One Injection of MenACWY-CRM Vaccine in the Present Study.	Day 1 to day 7 post-vaccination	The number of subjects reporting solicited local and systemic adverse events after one injection of MenACWY-CRM vaccine was administered in the present study to, 1. Subjects, who had 5 years earlier received either one or two doses of MenACWY-CRM vaccine 2. Vaccine-naive subjects.
Number of Subjects Reporting Unsolicited Adverse Events, After Receiving One Injection of MenACWY-CRM Vaccine in the Present Study.	Day 1 to day 28	The safety and tolerability of one injection of MenACWY-CRM vaccine, administered in the present study, was evaluated in terms of the number of subjects reporting unsolicited adverse events, serious adverse events and adverse events leading to premature withdrawal.

Trial Locations

Locations (16): 31 Benchmark Research, Fort Worth 4504 Boat Club Rd., Suite 400A
🇺🇸
Ft. Worth, Texas, United States
32 Prem Health Research Center 9317 Firestone Blvd.
🇺🇸
Downey, California, United States
65 Westside Medical 1477 N 2000 W, Suite C
🇺🇸
Clinton, Utah, United States
37 Copperview Medical Associates 3556 West 9800 South
🇺🇸
South Jordan, Utah, United States
30 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
🇺🇸
Salt Lake City, Utah, United States
47 Wee Care Pediatrics 1792 W. 1700 S.
🇺🇸
Syracuse, Utah, United States
26 Benchmark Research 3800 Houma Blvd., Suite 345
🇺🇦
Metairie, LA, Ukraine
34 Rockwood Clinic P S 400 East Fifth Avenue
🇺🇸
Spokane, Washington, United States
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
🇺🇸
Bentonville, Arkansas, United States
25 Benchmark Research, San Angelo 3555 Knickerbocker Rd.
🇺🇸
San Angelo, Texas, United States
29 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
🇺🇸
Salt Lake City, Utah, United States
35 Rockwood Clinic-North Pediatrics 9001 N Country Homes Blvd
🇺🇸
Spokane, Washington, United States
83 AR Pediatric Clinical Research 500 South University, Ste. 200
🇺🇸
Little Rock, Arkansas, United States
27 KY Pediatric Adult Research 201 South 5th Street, Suite 102
🇺🇸
Bardstown, Kentucky, United States
36 Meridian Clinical Research 3319 N. 107th Street
🇺🇸
Omaha, Nebraska, United States
33 Dr. Sender's and Associates 2054 South Green Road
🇺🇸
Cleveland, Ohio, United States